Naeve Gregory S. 4
4 · BELLICUM PHARMACEUTICALS, INC · Filed Jul 5, 2018
Insider Transaction Report
Form 4
Naeve Gregory S.
Sr. VP, Chief Business Officer
Transactions
- Award
Stock Option (right to buy)
2018-07-02+34,125→ 34,125 totalExercise: $7.72Exp: 2028-07-01→ Common Stock (34,125 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.